The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
Plus, what's going on with Lexicon Pharmaceuticals?
The slowest part of the trading year is setting up for the most volatile month.
The energy company takes a hit after earnings, but there's still reason for optimism.
The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.
Just five non-biotech names trade below net current asset value.
Small biotech tanked on weak earnings, but still seems promising.
I expect Allergan or another player to bid for SGYP soon.
These have positive momentum and good growth.
The continued growth in housing starts is a good sign for homebuilders in the new year, says Stocks Under $10 Portfolio Manager David Peltier.